6640--VAPAHCS Hematoxylin and Eosin Staining (H&E), Immunohistochemistry (IHC), In-Situ Hybridization (ISH), and Special Staining System Cost per Test (CPT)

The Department of Veterans Affairs Veterans Health Administration Network 21 is seeking quotes for a Cost per Test (CPT) contract to provide Hematoxylin and Eosin Staining (H&E), Immunohistochemistry (IHC), In-Situ Hybridization (ISH), and Special Staining services for the VA Palo Alto Health Care System. The procurement requires vendors to provide one automated H&E stainer, two IHC/ISH analyzers, and two Special Stains analyzers with specific technical capabilities including bar code tracking, fully automated processes, STAT capabilities, and in-line coverslipping (though this requirement has been modified to accept instruments without this feature). Vendors must demonstrate compliance with the Statement of Work through detailed technical proposals and complete required representations and certifications. The solicitation originally had a quote submission deadline of June 23, 2025, but has been extended to June 30, 2025, at 12:00 PM Mountain Daylight Time, while the question period closed on June 11, 2025. The contract will be evaluated based on technical compliance and pricing under the specified NAICS code 334516 for Analytical Laboratory Instrument Manufacturing.

This solicitation is set aside for small businesses and will result in a Firm-Fixed-Price, Indefinite-Delivery Indefinite-Quantity (IDIQ) agreement with a guaranteed minimum award of $100 and a maximum aggregate value of $2,250,000. The contract will cover five ordering periods spanning from October 1, 2025, through September 30, 2030, with an estimated annual volume of 27,000 to 32,000 H&E slides. Performance will take place at the VA Palo Alto Health Care System, with comprehensive service requirements including 4-hour emergency response times, 72-hour field engineer arrival, and 24/7 technical support. The contractor must provide pre-filled, FDA-approved reagent kits and maintain quality standards through pathology reports and monthly Quality Management Dashboard reporting. No incumbent contractors or current service providers are identified in the solicitation documents.